InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

26 April 2025

Name:	RESAPP HEALTH LIMITED (RAP)
ISIN:	AU000000RAP5
Date of Listing:	12 January 2005
Date of Delisting:	27 September 2022
Former Names:

Stock Exchange Status: (updated daily)

This entity was delisted from the Australian Securities Exchange on 27 September 2022.

Legal Status: (updated monthly)

ACN: 094 468 318ABN: 51 094 468 318
Registration Date: 13 September 2000

To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. We have not therefore verified the current legal status of this entity. If you have questions about your shareholding, as we say elsewhere, they may be taken up here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

RESAPP HEALTH LIMITED(RAP)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

	FROM	TO
NARHEX LIFE SCIENCES LIMITED		08/07/2015

Shareholder links

Our website ranking of RAP:

(5 out of 5)

COMPANY WEBSITE:

RAP website

RAP email

RAP investorRelations

RAP announcements

RAP annualreports

RAP directors

REGISTRY:

Level 5, 191 ST GEORGES TERRACE PERTH WA 6000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000RAP5

Address: Level 12, 100 Creek Street Brisbane QLD 4000
Tel: (07) 3724 0035 Fax: (08) 9218 8875

Date first listed: 12/01/2005
Company Secretary:
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Research and development of digital healthcare solutions for respiratory disease

News & Events

Expand this box to read and print

delisted at entity's request under Listing Rule 17.11	27/09/2022
we understand Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) acquired all of the issued shares in RAP for $0.208 cash per share	27/09/2022
The company releases a notification of cessation of securities.	16/09/2022
The securities of ResApp Health Limited will be suspended from quotation at the close of trading on Thursday, 15 September 2022 under Listing Rule 17.2, following lodgement of the Supreme Court of New South Wales orders with ASIC approving the scheme of arrangement by which Pfizer Australia Holdings Pty Limited will acquire all of the issued shares in RAP.	15/09/2022
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement.	14/06/2022
ResApp Health and Pfizer have agreed to increase the scheme consideration from A$0.115 per share in cash to: A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout Condition (Confirmed Data Consideration); or A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is not satisfied (Unconfirmed Data Consideration). Relative to ResApp's share price prior to announcement of the Initial Scheme, the Revised Scheme Consideration represents a material premium of: 130.0% based on the Confirmed Data Consideration, 62.2% based on the Unconfirmed Data Consideration. Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable and in best interests of ResApp shareholders. The ResApp Board unanimously recommends that ResApp shareholders vote in favour of the Revised Scheme.	14/06/2022
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the update on the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Tuesday 14 June 2022.	08/06/2022
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Wednesday 8 June 2022.	06/06/2022
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement.	02/06/2022
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding its COVID-19 study results.	22/03/2022
92% sensitivity for detecting COVID-19 with a new cough audio-based algorithm "“ exceeding the real-world measured sensitivity of rapid antigen testing. Initial market opportunities in settings where frequent testing is required "“ employee, healthcare worker and student screening, travel, sports, entertainment, and aged care. ResApp to engage with regulators on requirements for approvals and seek to partner with a global health or technology company to accelerate commercialisation.	22/03/2022
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its COVID-19 study results.	21/03/2022
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately, following the release by RAP of an announcement.	30/10/2018
The company announces positive preliminary results from its SMARTCOUGHC-2 study, a double-blind, prospective study to evaluate the efficacy of the ResAppDx smartphone application for the diagnosis of childhood acute respiratory disease.	30/10/2018
Further to the request for Voluntary Suspension on 24 October 2018, ResApp Health Limited advises that it has received the US SMARTCOUGH-C-2 study results and is currently in the process of analysing these results. The Company anticipates that it will be in a position to release a full update to the market on Tuesday 30 October 2018.	29/10/2018
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis.	24/10/2018
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following receipt of an announcement.	09/08/2017
The company announced top line data from its multi-site double-blind prospective clinical study to investigate ResAppDx for the diagnosis for respiratory disease in infants and children using cough sounds.	09/08/2017
The securities of ResApp Health Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to its SMARTCOUGH-C study.	02/08/2017
The securities of ResApp Health Limited (the "Company") will be reinstated to official quotation as from 10 am EST on Tuesday, 14 July 2015, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules. 440,523,353 ordinary shares fully paid Security Code RAP	09/07/2015
name changed from Narhex Life Sciences Limited	08/07/2015

delisted at entity's request under Listing Rule 17.11	27/09/2022
we understand Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) acquired all of the issued shares in RAP for $0.208 cash per share	27/09/2022
The company releases a notification of cessation of securities.	16/09/2022
The securities of ResApp Health Limited will be suspended from quotation at the close of trading on Thursday, 15 September 2022 under Listing Rule 17.2, following lodgement of the Supreme Court of New South Wales orders with ASIC approving the scheme of arrangement by which Pfizer Australia Holdings Pty Limited will acquire all of the issued shares in RAP.	15/09/2022
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement.	14/06/2022
ResApp Health and Pfizer have agreed to increase the scheme consideration from A$0.115 per share in cash to: A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout Condition (Confirmed Data Consideration); or A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is not satisfied (Unconfirmed Data Consideration). Relative to ResApp's share price prior to announcement of the Initial Scheme, the Revised Scheme Consideration represents a material premium of: 130.0% based on the Confirmed Data Consideration, 62.2% based on the Unconfirmed Data Consideration. Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable and in best interests of ResApp shareholders. The ResApp Board unanimously recommends that ResApp shareholders vote in favour of the Revised Scheme.	14/06/2022
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the update on the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Tuesday 14 June 2022.	08/06/2022
The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Wednesday 8 June 2022.	06/06/2022
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement.	02/06/2022
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding its COVID-19 study results.	22/03/2022
92% sensitivity for detecting COVID-19 with a new cough audio-based algorithm "“ exceeding the real-world measured sensitivity of rapid antigen testing. Initial market opportunities in settings where frequent testing is required "“ employee, healthcare worker and student screening, travel, sports, entertainment, and aged care. ResApp to engage with regulators on requirements for approvals and seek to partner with a global health or technology company to accelerate commercialisation.	22/03/2022
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its COVID-19 study results.	21/03/2022
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately, following the release by RAP of an announcement.	30/10/2018
The company announces positive preliminary results from its SMARTCOUGHC-2 study, a double-blind, prospective study to evaluate the efficacy of the ResAppDx smartphone application for the diagnosis of childhood acute respiratory disease.	30/10/2018
Further to the request for Voluntary Suspension on 24 October 2018, ResApp Health Limited advises that it has received the US SMARTCOUGH-C-2 study results and is currently in the process of analysing these results. The Company anticipates that it will be in a position to release a full update to the market on Tuesday 30 October 2018.	29/10/2018
The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis.	24/10/2018
The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following receipt of an announcement.	09/08/2017
The company announced top line data from its multi-site double-blind prospective clinical study to investigate ResAppDx for the diagnosis for respiratory disease in infants and children using cough sounds.	09/08/2017
The securities of ResApp Health Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to its SMARTCOUGH-C study.	02/08/2017
The securities of ResApp Health Limited (the "Company") will be reinstated to official quotation as from 10 am EST on Tuesday, 14 July 2015, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules. 440,523,353 ordinary shares fully paid Security Code RAP	09/07/2015
name changed from Narhex Life Sciences Limited	08/07/2015

Your browser may reflect a date of printing in American format.

ASX Announcements (courtesy of ASX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Purchases Sales

DATE	DIRECTOR	NUMBER	PRICE	AMOUNT
15/03/2021	Roger Aston	290,000	$0.070	$20,300.00
15/03/2021	Anthony Keating	225,000	$0.072	$16,200.00
15/03/2021	Chris Ntoumenopoulos	500,000	$0.071	$35,500.00
05/10/2017	Brian Leedman	875,885	$0.074	$64,512.00
09/08/2017	Chris Ntoumenopoulos	1,000,000	$0.073	$72,822.00

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
Roger Aston	Non Exec Chairman	17/07/2015
Anthony Keating	Managing Director, CEO	02/07/2015
Chris Ntoumenopoulos	Non Exec Director	22/01/2015
Robert Ramsay	Non Exec Director	20/12/2013
Michael Stein	Non Exec Director	06/04/2020
Brian Leedman	Executive Director	22/02/2016
Nicki Farley	Company Secretary

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.